Reaction
Nail Operation reporting signals
As of the last recalculation, Nail Operation appears in 406 FAERS reports alongside 23 co-occurring drug terms. The strongest observed disproportionality signal is PSEUDOEPHEDRINE HYDROCHLORIDE (PRR 310.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pseudoephedrine Hydrochloride | 54 | 310.6 | 312.3 |
| Pseudoephedrine Hcl | 55 | 295.8 | 297.3 |
| Cortisone Acetate | 56 | 269.6 | 270.8 |
| Desoximetasone | 57 | 178.3 | 178.8 |
| Diclofenac Potassium, Film Coated | 17 | 108.0 | 108.3 |
| Diclofenac Potassium Tablets | 17 | 108.0 | 108.2 |
| Cetirizine Hydrochloride Allergy | 48 | 92.0 | 92.2 |
| Cetirizine Hydrochloride Tablets | 48 | 92.0 | 92.1 |
| Diclofenac Potassium | 17 | 84.1 | 84.3 |
| Tofacitinib Citrate | 15 | 60.9 | 60.9 |
| Diclofenac Sodium 1% | 38 | 60.1 | 60.1 |
| Diclofenac Sodium Topical | 38 | 60.1 | 60.1 |
| Diclofenac Sodium Topical Gel, 1% | 38 | 59.9 | 60.0 |
| Golimumab | 67 | 47.8 | 47.8 |
| Sulfasalazine | 61 | 46.9 | 46.9 |
| Cetirizine | 55 | 41.9 | 41.9 |
| Certolizumab Pegol | 77 | 41.3 | 41.4 |
| Hydroxychloroquine | 50 | 39.0 | 39.0 |
| Tocilizumab | 66 | 35.2 | 35.2 |
| Cetiirizine | 27 | 34.9 | 35.0 |
| Abatacept | 71 | 31.6 | 31.7 |
| Botulinum Toxin Type A | 6 | 25.1 | 25.1 |
| Sarilumab | 9 | 17.8 | 17.8 |